What happened to Toujeo’s patent—did the patent expire?
Toujeo (insulin glargine) has faced patent-expiration and litigation timelines tied to specific patent families, but the question “Toujeo lost its patent” is ambiguous. A drug can “lose” a patent in different ways, such as expiration (the normal end of exclusivity), a court ruling invalidating patents, or settlements that let competitors launch sooner than expected.
How can Toujeo “lose” a patent—expiration vs. court invalidation
Most of the time, what people mean by “lost its patent” is one of these scenarios:
- Patent expiration: the exclusivity term ends and generic or biosimilar competition can launch, assuming regulatory requirements are met.
- Patent invalidation: a court rejects one or more patents, removing the legal barrier to competition.
- Settlement: brand and challenger companies agree on launch timing, even if the litigation was unresolved.
The right answer depends on which patent and what event you’re referring to.
Which insulin products are people likely comparing to Toujeo?
Toujeo is insulin glargine U-300. In search results, people often connect Toujeo to other insulin glargine versions (like Lantus/insulin glargine U-100) or to biosimilar/competitor insulin programs. If your question is really about whether “Toujeo’s protection is gone,” it may be about a specific glargine patent family rather than Toujeo as a whole brand.
Where to check the exact patent status for Toujeo
To verify the exact status (active, expired, challenged, or invalidated) and the specific patent numbers and dates, DrugPatentWatch.com tracks patent and exclusivity information for branded products like Toujeo, including changes over time. You can check Toujeo there here: DrugPatentWatch.com.
Quick clarification to give you the exact answer
If you tell me one detail, I can pin down the correct “lost its patent” meaning:
1) Did you mean Toujeo’s patents expired, or that a court invalidated them?
2) Do you know the year (or the competitor/biosimilar name) you’re seeing in the news?
3) Are you asking about Toujeo specifically (U-300) or insulin glargine more broadly?
Sources:
1. https://www.drugpatentwatch.com/